Schedule of Events

2019 ASCP Annual Meeting Schedule

 *of special interest to clinicians

 Monday, May 27, 2019
 8:00 AM  New Investigator Award (NIA) Workshop (Invitation Only)
 Tuesday, May 28, 2019
 8:30 AM  Conference Opening
 9:00 AM – 10:30 AM  Panel Sessions

  • Clinical Trial Designs that Move Psychopharmacology Towards Personalized Medicine
  • Treatment-resistant Mood Disorders Across the Lifespan: Novel Therapeutics on the Horizon*
  • New and Hopefully Improved! Novel Delivery Systems of Antipsychotic Medications for the Treatment of Schizophrenia*
  • Pharmacogenomic Testing in Psychiatric Practice: Does it Deliver what it Promises?*
 10:30 AM – 10:45 AM  Break
 10:45 AM – 12:15 PM  Panel Sessions

  • Leveraging Prior Experience to Facilitate Pediatric Clinical Development for Psychiatry Products*
  • Digital Technology Advancements and Potential for Assessing Behavior in Clinical Trials*
  • New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder*
  • Biomarker Development in Autism: The Potential Impact of the Autism Biomarkers Consortium for Clinical Trials (ABC-CT)*
 12:15 PM – 1:45 PM  Early Career Luncheon (RSVP Only)
 2:00 PM – 4:00 PM  Pharmaceutical Pipelines
 4:00 PM – 4:15 PM  Break
 4:15 PM – 5:30 PM  Individual Research Reports
 6:15 PM – 7:45 PM  New Investigator Awards Ceremony
 Wednesday, May 29, 2019
 6:30 AM Annual ASCP Fun Run/Walk – Open to All Attendees
 8:30 AM – 10:00 AM Regulatory Plenary

  •   William Potter, MD, PhD, NIMH, Chair
  •   Tiffany Farchione, MD, FDA: Breakthrough Therapy Program and Products in the Psychiatry Pipeline.
  •   Valentina Mantua, MD, AIFA: Comparing Breakthrough Therapy and Prime, Including Assessment, Timelines, Benefits, Outcomes, and Regulatory Pathways.
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:15 AM  ASCP Lifetime Awardee Talk
 11:15 AM – 1:00 PM  Poster Session I with Lunch
 1:00 PM – 2:30 PM  Panel Sessions

  • Adapting Treatment Outcomes of Major Depressive Disorder as Research Evolves: How Biomarkers, Functional Measures, and Associated Features can Inform the Definition of Response and Remission*
  • Developing an Advanced CNS Clinical Trial Course
  • Bad Behavior in Clinical Trials: Strategies to Combat Research Participant Dishonesty/Deception, Non-adherence, and “Professional subjects”*
  • Towards the Implementation of Pharmacogenetics in Psychiatry*
 2:30 PM – 2:45 PM  Break
 2:45 PM – 4:45 PM  Workshop Sessions

  • Negotiation Strategies for Professionals in CNS Research: A Mid-Career Mentoring Workshop*
  • ASCP-ISBD Workshop: Update on Treatment of Bipolar Disorder*
  • Early Career Workshop: How to Give a Scientific Presentation
  • ASCP-AFSP Workshop
 5:00 PM – 6:00 PM  ASCP Business Meeting and Reception (Members Only)
 6:00 PM – 7:00 PM  ASCP Reception
 Thursday, May 30, 2019
 8:15 AM – 9:45 AM  Keynote Plenary

  •  Madhukar Trivedi, MD, UT Southwestern, Chair and Moderator: Dissemination and Implementation of Personalized Medicine.
  •  Holly Gariock, PhD, University California, San Diego, All of Us Research Program: Ways to Engage the Scientific Community to Contribute Ideas, Cases, Questions and Collaborative Adjunct Projects.
  •  Jordan Smoller, MD, ScD, Harvard Medical School: Psychiatry and Substance Abuse Aspects of the All of Us Research Program.
 9:45 AM – 10:00 AM  Break
 10:00 AM – 12:30 PM  Federal Agency Updates Plenary

  •   Michael Thase, MD, Perelman School of Medicine at the University of Pennsylvania, Chair
  •   George Koob PhD, NIAAA
  •   Bruce Cuthbert, PhD, NIMH
  •   Kurt Rasmussen, PhD, NIDA
  •   Terri Gleason, PhD, VA
  •   Christopher Austin, MD, NCATS
  •   Elinore McCance-Katz, MD, PhD, SAMHSA
 12:30 PM – 2:00 PM  Poster Session II with Lunch
 2:00 PM – 3:30 PM Clinical Updates in Psychopharmacology Session*
 3:30 PM – 3:45 PM  Break
 3:45 PM – 5:45 PM  Workshop Sessions

  • Methodological Challenges in Implementing Clinical Trials to Address the Questions Posed in Developing Personalized Medicine Treatments
  • Psychedelic Drug Development: Perspectives from the Division of Psychiatry Products, Us Food and Drug Administration*
  • TMS, Ketamine or ECT: 3 Case Presentations
  • Where Do We Stand with the Use of the Sequential Parallel Comparison Design in CNS Drug Trials? an Update 16 Years Later
 Friday, May 31, 2019
 8:30 AM – 10:00 AM  Panel Sessions

  • Repurposing Drugs for Schizophrenia: Insights from Immune and Renin-Angiotensin Systems*
  • CNS Clinical Trials in China: Achievements, Challenges, and Opportunities*
  • Second-Generation Glutamatergic Agents for Major Depressive Disorder*
  • Nonstimulants for ADHD: Rationale, Emerging treatments, and the Role of Biomarkers*
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:45 AM  Regulatory Wrap-Up Plenary
  William Potter, MD, PhD, NIMH, Chair
  Tiffany Farchione, MD, FDA
  Valentina Mantua, MD, AIFA
 12:00 PM  Meeting Adjourns

 *of special interest to clinicians